BPC-157 + TB-500 20mg

BPC-157 + TB-500 20mg — Dual Research Blend

This BPC-157 + TB-500 20mg blend combines two of the most extensively studied tissue repair peptides — BPC-157 (10mg) and TB-500 (10mg) — in a single lyophilised vial at ≥99% purity. The pairing is among the most commonly studied multi-peptide combinations in regenerative biology research, as the two compounds operate through distinct but complementary mechanisms that provide broader pathway coverage than either compound alone.

UK-dispatched by OL Research. For laboratory research use only.

Why This Combination is Studied

BPC-157 and TB-500 have overlapping research applications in tissue repair but act through fundamentally different molecular pathways:

• BPC-157 operates primarily via the nitric oxide (NO) system and VEGF-mediated angiogenesis; it has the strongest evidence base in gastrointestinal mucosal protection and tendon-to-bone healing models
• TB-500 operates via actin sequestration and GHS-1a receptor-independent cell migration; its strongest evidence base is in cardiac muscle, skeletal muscle, and skin wound healing models

The combination is studied to investigate whether the two pathways exhibit additive or synergistic effects across tissue repair endpoints — a question that would be difficult to study with either compound alone. Pre-blended combination vials also ensure consistent compound ratios across experimental replicates.

Product Specifications

Key Questions

Why buy the blend rather than separate vials?
For research protocols requiring a fixed 1:1 ratio of BPC-157 and TB-500, a pre-blended vial eliminates the separate reconstitution and mixing steps, reducing preparation variability and the risk of cross-contamination between vials. It also simplifies the reconstitution process for longitudinal protocols.

Can the individual compounds be studied separately if needed?
No — once blended, the compounds cannot be separated. For research requiring independent administration of BPC-157 and TB-500, the individual products should be purchased separately.

Is this for human use?
No. Supplied strictly for laboratory research use only.

Practical Considerations for BPC-157 + TB-500 Co-Administration Research

The 1:1 dose ratio (10mg BPC-157 + 10mg TB-500) in this blend was selected to mirror the most commonly reported combination protocol in published preclinical literature. Co-lyophilising the two compounds in a single vial at ≥99% purity per compound provides three practical research advantages over reconstituting and dosing each compound separately:

• Same-batch consistency — researchers compare combined effects without inter-vial purity, lot, or batch-date variation between the two peptides confounding the result
• Reduced reconstitution steps — a single bacteriostatic-water reconstitution prepares both compounds simultaneously, eliminating the QC overhead of two separate vials in extended-protocol or multi-arm work
• Aligned in-use stability — both peptides share the same reconstitution date and storage history, simplifying time-course study design

For most research protocols a 2ml bacteriostatic water reconstitution yields a 5mg/ml BPC-157 + 5mg/ml TB-500 working solution. Researchers studying the individual compounds separately may prefer the standalone BPC-157 10mg and TB-500 10mg preparations; researchers studying a broader regenerative pathway combination including copper-peptide remodelling or anti-inflammatory signalling will find the higher-complexity KLOW 80mg blend more appropriate.

Related Research Compounds

• BPC-157 10mg — Individual BPC-157 research compound
• TB-500 10mg — Individual TB-500 research compound
• KLOW 80mg — Multi-peptide high-dose research blend including BPC-157 and TB-500

⚠️ For laboratory and in-vitro research use only. Not for human consumption, veterinary use, or clinical application.